Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients

[1]  J. Zwicker,et al.  Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study , 2021, Haematologica.

[2]  M. Griesshammer,et al.  Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients , 2021, Leukemia.

[3]  S. Middeldorp,et al.  A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. , 2021, Blood advances.

[4]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[5]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism , 2019, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[6]  T. Barbui,et al.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. , 2019, Blood advances.

[7]  G. Agnelli,et al.  ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM. , 2019, Blood.

[8]  T. Barbui,et al.  Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms , 2018, Blood Cancer Journal.

[9]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Mccarroll,et al.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[11]  P. Dickman,et al.  Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms , 2018, Annals of Internal Medicine.

[12]  S. Krichevsky,et al.  Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. , 2016, European journal of internal medicine.

[13]  M. Prins,et al.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism , 2017, The New England journal of medicine.

[14]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[15]  M. Griesshammer,et al.  High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists , 2016, Leukemia.

[16]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  T. Barbui,et al.  Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia , 2015, Blood Cancer Journal.

[18]  R. De Cristofaro,et al.  Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count , 2015, Journal of thrombosis and haemostasis : JTH.

[19]  P. Lambert,et al.  Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. González-Porras,et al.  Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia , 2015, Annals of Hematology.

[21]  T. Barbui,et al.  In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. , 2014, Blood.

[22]  T. Golub,et al.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. , 2014, Blood.

[23]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[24]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[25]  M. De Grandis,et al.  JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. , 2013, Blood.

[26]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[27]  P. Campbell,et al.  Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. , 2012, Blood.

[28]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[29]  T. Barbui,et al.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. , 2011, Blood.

[30]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[31]  T. Barbui,et al.  Thrombosis in primary myelofibrosis: incidence and risk factors. , 2009, Blood.

[32]  T. Schiano,et al.  The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. , 2009, Blood.

[33]  T. Barbui,et al.  Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments , 2008, Haematologica.

[34]  N. Villamor,et al.  Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.

[35]  T. Barbui,et al.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.